Employees: 632
Size AngioDynamics (ANGO) is a United States Health Care company (Medical Specialties) with a market value of $476M, the 2705th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.32 on 18 Nov 2026.
Performance Over six months the shares fell 4.2%, against -20.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +1.9%); the operating margin is -6.0% (peer median 2.7%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 2.7× (3rd cheapest of 19).
Capital Return on invested capital runs 17.5 points below its cost of capital (6.5% WACC).
Short interest Short interest is 4.8% of the free float (30 Oct 2026).
Next results Next results expected around 7 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $325M | $320M | $292M | $304M | $339M |
| Revenue growth | — | +9% | -4% | -10% | — |
| Gross profit | $170M | $164M | $147M | $142M | $155M |
| EBITDA | $2.88M | -$1.15M | -$244,000 | -$6.10M | $14.5M |
| Net income | -$32.9M | -$36.7M | -$34.0M | -$184M | -$52.4M |
| Free cash flow | -$3.87M | -$2.86M | -$21.0M | -$35.7M | -$9.13M |
| Capital expenditure | $7.55M | $5.95M | $10.2M | $10.8M | $9.75M |
| Total debt | $10.7M | $11.0M | $3.95M | $5.91M | $55.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANGO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -6.1% | 10th highest of 21 |
| 6-month return | -4.2% | -20.2% | 5th highest of 21 |
| Distance from 52-week high | -30.5% | -43.4% | 5th highest of 21 |
| Revenue growth (TTM) | +8.2% | +1.9% | 7th highest of 20 |
| Operating margin | -6.0% | 2.7% | 8th lowest of 20 |
| EV / Sales | 1.4× | 2.7× | 3rd cheapest of 19 |
| ROIC minus cost of capital | -17.5 pp | -1.6 pp | 2nd lowest of 18 |
| Net debt / EBITDA | -8.1× | -1.0× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | 1.4× | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 6.1× | 7.1% | +10.0% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | 3.1× | 55.3% | -4.7% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 2.0× | -5.9% | +7.7% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 7.0× | 4.3% | +24.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 1.3× | -6.5% | -4.3% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 1.6× | n/a | n/a |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | 1.1× | 10.9% | +11.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 2.2× | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | 8.2× | 36.0% | -6.9% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | 410.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 1.4× | 4.5% | +5.0% |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 5.3× | 20.1% | +4.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | 1.6× | n/a | n/a |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 3% | 3.8× | 21.5% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 10% | 1.5× | -1.0% | -2.8% |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | 5.4× | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | 125.0× | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 1.6× | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | n/a | n/a | n/a | n/a |